GRADE 3B FOLLICULAR LYMPHOMA

This study tests a drug called epcoritamab in 30 people with a type of blood cancer (large B-cell lymphoma) that has come back or not responded to treatment. Participants cannot have a stem cell transplant. The goal is to see if the drug can control the cancer for at least 12 mon…

This early-phase trial tests a new injection called IASO207 for people with relapsed or refractory B-cell blood cancers. Unlike current CAR-T therapies that require removing and engineering cells in a lab, IASO207 is designed to create cancer-fighting T cells directly inside the …

This early study is testing an injection called IASO208 in 12 adults with certain types of blood cancer that have returned or not improved with standard treatments. The main goal is to see if the treatment is safe and to find the right dose. Researchers will also look at how well…

This study tests whether adding two targeted drugs (mosunetuzumab and/or polatuzumab vedotin) after standard CAR T-cell therapy can help control lymphoma that has returned or not responded to treatment. About 396 adults with certain types of aggressive B-cell lymphoma will be ran…

This study tests whether adding three targeted antibodies (tafasitamab, retifanlimab, and rituximab) to standard chemotherapy can safely treat people with untreated diffuse large B-cell lymphoma. About 35 adults will receive the antibody combination before and during chemo. The g…

This phase 3 trial tests a new CAR T-cell therapy called rondecabtagene autoleucel (ronde-cel) that targets two proteins (CD19 and CD20) on lymphoma cells. It is compared to standard CD19-targeting CAR T-cell therapy in 400 patients with relapsed or refractory large B-cell lympho…

This early-phase study tests a new type of immune cell therapy (CAR T cells) that targets two proteins, CD79b and CD19, on lymphoma cells. It is for people with non-Hodgkin lymphoma whose cancer has returned or stopped responding to standard treatments. The main goals are to chec…

This study tests whether adding either tazemetostat or zanubrutinib to a standard two-drug therapy (tafasitamab and lenalidomide) can shrink tumors or delay cancer return in people with large B-cell lymphoma that came back or didn't respond to prior treatment. About 227 adults wh…

This study looks at whether measuring tumor DNA in the blood (ctDNA) can help doctors tailor treatment for people with early-stage diffuse large B-cell lymphoma (DLBCL). About 40 participants will receive standard chemotherapy (R-CHOP) and have their ctDNA levels checked alongsid…